Research

Informing Clinical Practice

Mr Addison has been involved in high quality basic-science and clinical research throughout his career. 


As a medical student at Cambridge, he obtained a First Class degree , one third of which was awarded for original laboratory research.


During two years of post-graduate research, Mr Addison discovered novel molecular genetic causes of inherited cataracts.


As a Consultant, he has continued active involvement in research:

Co-investigator on 13 different international clinical trials:

  • wet and dry age-related macular degeneration
  • retinal vein occlusion
  • uveitis
  • novel gene therapy for inherited eye disease

Principal investigator for 2 further studies:

  • a national study on the genetics of steroid induced intra-ocular pressure rise
  • an international randomised controlled trial on central retinal vein occlusion.

Full list of more than 60 publications:

https://scholar.google.com/citations?hl=en&user=EEuPBucAAAAJ&view_op=list_works

Recent Publications in Peer Reviewed Journals

  1. Intraocular Pressure Spikes after Intravitreal Injections: A Fifteen-Year Retrospective Study. Accepted for publication in Eye September 2026.
  2. Performance of automated anterior segment OCT-based quantitative imaging in adult interior chamber inflammation. MedRxiv July 2026.
  3. Real-world early outcomes of intravitreal faricimab 6-mg and aflibercept 2-mg injection in diabetic macular oedema. British Journal of Ophthalmology, April 2026
  4. Real-World Experience of Fluocinolone Acetonide 0.19 mg in the Management of Non-Infectious Uveitis.  Ocul Immunol Inflamm. Published online July 2024.
  5. Adalimumab in the treatment of refractory non-infectious scleritis: 6 month outcomes. Eye September 2023.
  6. Birdshot retinochoroiditis. Eye News June/July 2022; vol 29:1 
  7. Multifocal evanescent white dot syndrome-like phenotypes associated with inflammatory and myopic choroidal neovascularization . Ocul Immunol Inflamm. June 2021
  8. Severe hypotony-induced intraocular inflammation after removal of ripcord suture from a glaucoma drainage device in uveitis patient . Ocul Immunol Inflamm. April 2021.
  9. Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial. Ophthalmology and Therapy September 2020; 9(3):563-576.
  10. Real-life evidence for using a treat-and-extend injection regime for patients with central retinal vein occlusion . Ophthalmology and Therapy April 2019; 8:289-296.

 

Latest Presentations at International Meetings 

  • Presentations on ocular steroid injections at the Moorfields Macular Course, London, annually since 2022
  • 2 presentations at the annual congress of the European Association for Vision and Eye Research, Florence, October 2026
  • 3 presentations at the EuRetina Annual Meeting, Vienna, September 2026
  • 1 presentation at the World Ophthalmology Congress, Prague, June 2026
  • 1 presentation for University of Cape Coast School of Optometry and Vision Science, Ghana June 2026
  • 8 presentations as Association for Research in Vision and Ophthalmology Annual Meeting, Denver, US May 2026
  • 1 presentation at the UK Royal College of Ophthalmologists Annual Conference, May 2026
  • 1 presentation at the Irish College of Ophthalmologists Annual Conference, May 2026